Cancer Blog


Development of a KRAS-Targeting PROTAC

Development of a KRAS Targeting PROTAC Banner

 

In this question-and-answer session, Michael Bond (Yale University) talks to our Senior Product Specialist, Alex Moloney PhD, about the development of a KRAS G12C-targeting PROTAC® which is now available from Tocris.


dTAG - A Protein Degradation Platform for Target Validation


Targeting the Immune System in Cancer with Small Molecules


RAS - The Undruggable Target

blog banner : RAS - The Undruggable Target

Long-termed the “undruggable target”, RAS has recently recaptured the attention of cancer researchers. A new understanding of this target has once again reignited hopes of modulating it to tackle some of the most lethal cancers.